FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311018441> ?p ?o ?g. }

• W4311018441 endingPage "90" @default.
• W4311018441 startingPage "77" @default.
• W4311018441 abstract "Background Adjuvant abemaciclib plus endocrine therapy previously showed a significant improvement in invasive disease-free survival and distant relapse-free survival in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2; also known as ERBB2)-negative, node-positive, high-risk, early breast cancer. Here, we report updated results from an interim analysis to assess overall survival as well as invasive disease-free survival and distant relapse-free survival with additional follow-up. Methods In monarchE, an open-label, randomised, phase 3 trial, adult patients (aged ≥18 years) who had hormone receptor-positive, HER2-negative, node-positive, early breast cancer at a high risk of recurrence with an Eastern Cooperative Oncology Group performance status of 0 or 1 were recruited from 603 sites including hospitals and academic and community centres in 38 countries. Patients were randomly assigned (1:1) by means of an interactive web-based response system (block size of 4), stratified by previous chemotherapy, menopausal status, and region, to receive standard-of-care endocrine therapy of physician's choice for up to 10 years with or without abemaciclib 150 mg orally twice a day for 2 years (treatment period). All therapies were administered in an open-label manner without masking. High-risk disease was defined as either four or more positive axillary lymph nodes, or between one and three positive axillary lymph nodes and either grade 3 disease or tumour size of 5 cm or larger (cohort 1). A smaller group of patients were enrolled with between one and three positive axillary lymph nodes and Ki-67 of at least 20% as an additional risk feature (cohort 2). This was a prespecified overall survival interim analysis planned to occur 2 years after the primary outcome analysis for invasive disease-free survival. Efficacy was assessed in the intention-to-treat population. Safety was assessed in all treated patients. The study is registered with ClinicalTrials.gov, NCT03155997, and is ongoing. Findings Between July 17, 2017, and Aug 12, 2019, 5637 patients were randomly assigned (5601 [99·4%] were women and 36 [0·6%] were men). 2808 were assigned to receive abemaciclib plus endocrine therapy and 2829 were assigned to receive endocrine therapy alone. At a median follow-up of 42 months (IQR 37–47), median invasive disease-free survival was not reached in either group and the invasive disease-free survival benefit previously reported was sustained: HR 0·664 (95% CI 0·578–0·762, nominal p<0·0001). At 4 years, the absolute difference in invasive disease-free survival between the groups was 6·4% (85·8% [95% CI 84·2–87·3] in the abemaciclib plus endocrine therapy group vs 79·4% [77·5–81·1] in the endocrine therapy alone group). 157 (5·6%) of 2808 patients in the abemaciclib plus endocrine therapy group died compared with 173 (6·1%) of 2829 patients in the endocrine therapy alone group (HR 0·929, 95% CI 0·748–1·153; p=0·50). The most common grade 3–4 adverse events were neutropenia (in 548 [19·6%] of 2791 patients receiving abemaciclib plus endocrine therapy vs 24 [0·9%] of 2800 patients in the endocrine therapy alone group), leukopenia (318 [11·4%] vs 11 [0·4%]), and diarrhoea (218 [7·8%] vs six [0·2%]). Serious adverse events occurred in 433 (15·5%) of 2791 patients receiving abemaciclib plus endocrine therapy versus 256 (9·1%) of 2800 receiving endocrine therapy. There were two treatment-related deaths in the abemaciclib plus endocrine therapy group (diarrhoea and pneumonitis) and none in the endocrine therapy alone group. Interpretation Adjuvant abemaciclib reduces the risk of recurrence. The benefit is sustained beyond the completion of treatment with an absolute increase at 4 years, further supporting the use of abemaciclib in patients with high-risk hormone receptor-positive, HER2-negative early breast cancer. Further follow-up is needed to establish whether overall survival can be improved with abemaciclib plus endocrine therapy in these patients. Funding Eli Lilly." @default.
• W4311018441 created "2022-12-22" @default.
• W4311018441 creator A5002068827 @default.
• W4311018441 creator A5004846711 @default.
• W4311018441 creator A5007579054 @default.
• W4311018441 creator A5008665323 @default.
• W4311018441 creator A5016921828 @default.
• W4311018441 creator A5027231412 @default.
• W4311018441 creator A5031915637 @default.
• W4311018441 creator A5032340945 @default.
• W4311018441 creator A5034863656 @default.
• W4311018441 creator A5036420234 @default.
• W4311018441 creator A5048281465 @default.
• W4311018441 creator A5056916984 @default.
• W4311018441 creator A5057317181 @default.
• W4311018441 creator A5059941445 @default.
• W4311018441 creator A5067146231 @default.
• W4311018441 creator A5068367016 @default.
• W4311018441 creator A5069056507 @default.
• W4311018441 creator A5071432873 @default.
• W4311018441 creator A5071553983 @default.
• W4311018441 creator A5074479074 @default.
• W4311018441 creator A5080186890 @default.
• W4311018441 creator A5084277231 @default.
• W4311018441 creator A5090188675 @default.
• W4311018441 creator A5091245889 @default.
• W4311018441 date "2023-01-01" @default.
• W4311018441 modified "2023-10-18" @default.
• W4311018441 title "Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial" @default.
• W4311018441 cites W1453600927 @default.
• W4311018441 cites W1531964529 @default.
• W4311018441 cites W1991601194 @default.
• W4311018441 cites W2096864872 @default.
• W4311018441 cites W2214665719 @default.
• W4311018441 cites W2592406193 @default.
• W4311018441 cites W2612124029 @default.
• W4311018441 cites W2767600184 @default.
• W4311018441 cites W2806209829 @default.
• W4311018441 cites W2981209325 @default.
• W4311018441 cites W3120241209 @default.
• W4311018441 cites W3130416374 @default.
• W4311018441 cites W3148345241 @default.
• W4311018441 cites W3206169364 @default.
• W4311018441 cites W3210178194 @default.
• W4311018441 cites W3217553653 @default.
• W4311018441 cites W4200389952 @default.
• W4311018441 cites W4206349107 @default.
• W4311018441 cites W4206939230 @default.
• W4311018441 cites W4220778872 @default.
• W4311018441 cites W4225751911 @default.
• W4311018441 cites W4225985995 @default.
• W4311018441 cites W4231018668 @default.
• W4311018441 cites W4281560766 @default.
• W4311018441 cites W4283786358 @default.
• W4311018441 doi "https://doi.org/10.1016/s1470-2045(22)00694-5" @default.
• W4311018441 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36493792" @default.
• W4311018441 hasPublicationYear "2023" @default.
• W4311018441 type Work @default.
• W4311018441 citedByCount "72" @default.
• W4311018441 countsByYear W43110184412023 @default.
• W4311018441 crossrefType "journal-article" @default.
• W4311018441 hasAuthorship W4311018441A5002068827 @default.
• W4311018441 hasAuthorship W4311018441A5004846711 @default.
• W4311018441 hasAuthorship W4311018441A5007579054 @default.
• W4311018441 hasAuthorship W4311018441A5008665323 @default.
• W4311018441 hasAuthorship W4311018441A5016921828 @default.
• W4311018441 hasAuthorship W4311018441A5027231412 @default.
• W4311018441 hasAuthorship W4311018441A5031915637 @default.
• W4311018441 hasAuthorship W4311018441A5032340945 @default.
• W4311018441 hasAuthorship W4311018441A5034863656 @default.
• W4311018441 hasAuthorship W4311018441A5036420234 @default.
• W4311018441 hasAuthorship W4311018441A5048281465 @default.
• W4311018441 hasAuthorship W4311018441A5056916984 @default.
• W4311018441 hasAuthorship W4311018441A5057317181 @default.
• W4311018441 hasAuthorship W4311018441A5059941445 @default.
• W4311018441 hasAuthorship W4311018441A5067146231 @default.
• W4311018441 hasAuthorship W4311018441A5068367016 @default.
• W4311018441 hasAuthorship W4311018441A5069056507 @default.
• W4311018441 hasAuthorship W4311018441A5071432873 @default.
• W4311018441 hasAuthorship W4311018441A5071553983 @default.
• W4311018441 hasAuthorship W4311018441A5074479074 @default.
• W4311018441 hasAuthorship W4311018441A5080186890 @default.
• W4311018441 hasAuthorship W4311018441A5084277231 @default.
• W4311018441 hasAuthorship W4311018441A5090188675 @default.
• W4311018441 hasAuthorship W4311018441A5091245889 @default.
• W4311018441 hasConcept C121608353 @default.
• W4311018441 hasConcept C126322002 @default.
• W4311018441 hasConcept C143998085 @default.
• W4311018441 hasConcept C168563851 @default.
• W4311018441 hasConcept C2777649267 @default.
• W4311018441 hasConcept C2777982462 @default.
• W4311018441 hasConcept C530470458 @default.
• W4311018441 hasConcept C61943457 @default.
• W4311018441 hasConcept C71924100 @default.
• W4311018441 hasConceptScore W4311018441C121608353 @default.
• W4311018441 hasConceptScore W4311018441C126322002 @default.
• W4311018441 hasConceptScore W4311018441C143998085 @default.
• W4311018441 hasConceptScore W4311018441C168563851 @default.

• next